Background: It has been reported that direct oral anticoagulants (DOAC) reduce cardiovascular
event in patients with atrial fibrillation (AF). We examined impacts of DOAC on mortality
in heart failure (HF) patients with AF. Methods and Results: Consecutive 352 hospitalized HF patients with AF were divided into 3 groups: non-anticoagulant
group (n = 67), Vit K antagonist (VKA) group (n = 210) and DOAC group (n = 75). In
Kaplan-Meier analysis, all-cause mortality was significantly higher in non-anticoagulant
group than in VKA and DOAC groups (P < .01). In multivariable analysis, the use of DOAC, but not VKA, was an independent
predictor of mortality in HF patients with AF (DOAC, HR 0.432, P = .038; VKA, HR 0.626, P = .070). Conclusion: Appropriate use of anticoagulants in HF patients with AF is important, and DOAC may
improve mortality in HF patients with AF.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
